Velocity Composites PLC (VEL:AIM) provided an investor update for the financial year ended 31 October 2025, outlining resilient company performance amid a still recovering aerospace and defence market. Revenue declined 10% to £20.7 million due to industry disruption and delayed programme transfers, but this was offset by strong operational progress, with gross margin improving from 26% to 29.5% and gross profit increasing year on year. Adjusted EBITDA more than doubled to just under £1 million, operating losses narrowed, and cash generation from operations remained robust, reflecting disciplined cost control, ERP driven efficiency gains, and improved working capital management. The company reduced inventory, improved debtor days, lowered finance costs, and expects to be largely debt free by FY 2027, supported by significant liquidity headroom via its invoice discounting facility. Strategically, Velocity is positioned for growth as industry conditions improve, with optimism returning across key civil and defence programmes including 737 MAX, A350, and long term defence platforms. The group is progressing a major US programme transfer, expanding senior level customer engagement, and leveraging available capacity across its UK, Europe, and US facilities. Long term contract renewals, a growing order book, and a focus on scalable forward stock locations underpin the growth strategy, as Velocity targets revenue growth, improved margins, and sustainable profitability as production rates increase through 2026 and beyond.

Genel Energy plc (GNEL:LSE) provided a January investor update outlining a resilient year-end performance and a clearly defined growth strategy despite operational and geopolitical challenges. The company reported strong company performance from its world-class, long-life Tauki PSC asset, with production recovering to approximately 80,000 barrels per day following a temporary Q3 outage and delivering double-digit underlying free cash flow even at domestic pricing. A strengthened balance sheet underpins the investment case, with net cash of around $134 million at year end, available liquidity of approximately $224 million, and materially reduced debt following refinancing, lowering funding risk and net interest costs. Management highlighted disciplined cost control, portfolio rationalisation, and operational efficiency as key drivers of improved margins, EBITDA resilience, and sustainable cash generation. Looking ahead, Genel Energy’s growth strategy focuses on value-accretive reinvestment at Tauki through low-cost drilling with rapid payback, potential upside from resuming international exports and accessing higher realised prices, and geographic diversification. Progress continues at Block 54 in Oman, where a multi-year seismic and drilling programme is planned, alongside steady advancement in Somaliland toward the high-impact Tucson-1 exploration well, targeting prospective resources of approximately 650 million barrels. The company remains active but disciplined in M&A, prioritising cash-generative assets at the right price to enhance long-term shareholder value. Overall, the update reinforces Genel Energy’s strong financial position, resilient free cash flow profile, and multiple catalysts for revenue growth into 2026.

Thor Explorations Ltd (THX:AIM) provided an investor update highlighting strong company performance, robust financial results and a clear growth strategy anchored by its West Africa gold portfolio. The company reported a highly successful year with gold production of approximately 92,000 ounces from its Segilola mine in Nigeria at all in sustaining costs below $1,000 per ounce, driving record revenue, expanding margins and a transition to a net cash position of around $100 million. Thor ended the year with $137 million in cash, returned approximately $18 million to shareholders through dividends and maintains a market capitalisation of about 1.14 billion Canadian dollars. The presentation focused on the preliminary feasibility study for the Dua gold project in Senegal, which outlines a long life mine of 12.5 years based on a probable reserve of 1.2 million ounces and a global resource approaching 2 million ounces. At a $3,500 gold price, the project delivers a pre tax NPV of $908 million, post tax NPV of $633 million, a rapid payback of under one year and a post tax IRR of 61%, supported by manageable capex of $254 million and strong early cash flow. Thor plans to fund development through existing cash and project finance with no shareholder dilution, while advancing a 40,000 metre drilling programme aimed at expanding the oxide resource and extending mine life. Ongoing exploration in Senegal and Cote d Ivoire, a disciplined capital return policy and a fully funded development pipeline position Thor for continued revenue growth and value creation for investors.

Kromek Group PLC (KMK:AIM) delivered a positive interim investor update highlighting improving company performance, a return to profitability and a clearly articulated growth strategy driven by advanced medical imaging and CBRN detection markets. The group reported solid H1 financial results supported by high margin licensing income from the Siemens enablement agreement, growing product revenues and stable gross margins, while confirming it is now cash generative with no intention of further equity dilution. Management reiterated its medium term target of £60 million in revenue with 30 percent EBITDA margins, underpinned by accelerating adoption of CZT technology across SPECT and CT imaging, where Kromek is the only independent commercial supplier with access to around 40 percent of a projected $400 million global CZT detector market by 2030. The company highlighted a strong order book including £4.8 million of year to date CBRN orders, expanding tier one OEM relationships and increasing visibility on future production ramps. Capacity expansion will be funded through structured customer contracts and existing debt facilities, limiting balance sheet risk. Administrative costs are expected to scale efficiently as revenues grow, while capital allocation remains focused on organic growth, internally funded R&D and selective bolt on M&A rather than dividends, reinforcing confidence in Kromek Group’s long term revenue growth, margin expansion and shareholder value creation.

Van Elle Holdings plc (VANL:AIM) delivered an investor update highlighting resilient company performance amid subdued construction markets, with early signs of recovery and a clearer growth trajectory. For the six months to October, revenue increased 16% year on year, supported by infrastructure and specialist piling activity, while profit before tax was marginally lower due to temporary margin pressures, competitive pricing and one prudent contract provision. Management reiterated confidence in achieving a 6% operating margin by FY28, underpinned by improving work mix, operational leverage and disciplined cost control, alongside a medium-term target of 15%+ return on capital employed. Infrastructure continues to grow as a proportion of revenue, particularly in energy and water, where Van Elle sees transformational growth potential, targeting up to £40m of incremental annual revenue by FY28 through frameworks, specialist capabilities and a new dedicated energy division. Residential markets remain subdued due to housebuilder caution and Building Safety Act delays, though approvals are accelerating and the London business is expected to return to breakeven by Q4. The order book edged higher, with additional unreported visibility from strategically embedded frameworks. The balance sheet remains strong following the disposal of the Canadian subsidiary post-period end, low net debt, healthy cash generation, continued dividends and a new £10m asset finance facility. Ongoing initiatives, including fleet optimisation, outsourcing of transport, design-led growth, selective bolt-on M&A and capital discipline, are expected to support sustainable margin improvement, EBITDA growth and long-term shareholder value.

ACG Metals Limited (ACG:LSE) provided an investor update outlining a transformational year as the company transitions from gold production to becoming a predominantly copper-focused producer. In FY2024, ACG outperformed guidance, delivering 39,000 ounces of gold equivalent, supported by strong operational execution, an 18% reduction in C1 costs, and robust margins amid higher gold prices. The company enters FY2025 with a clear growth strategy, maintaining gold and silver production from oxide stockpiles in H1 before commencing copper and zinc concentrate production from its sulphide expansion project in H2. Full-year guidance targets 15,000–17,000 tonnes of copper equivalent from sulphides, plus approximately 17,500 ounces of gold equivalent from oxides, positioning ACG as a high-grade, low-cost producer. The sulphide project is over 60% complete, on time and on budget, with commercial production expected by mid-year following commissioning. ACG highlighted strong liquidity, with project financing secured via a staged $200m bond, healthy cash generation, and manageable net debt. Cost guidance indicates copper production costs of around $2.50/lb during ramp-up, implying attractive EBITDA margins at current prices. Management also pointed to potential upside from improved mine sequencing, higher early copper grades, capital structure optimisation, increased market liquidity, and longer-term M&A opportunities. Overall, the presentation reinforced confidence in ACG’s operational performance, financial results, and long-term value creation strategy as it evolves into a diversified base metals producer.

EEnergy Group PLC delivered a robust investor update highlighting strong underlying company performance despite short-term revenue timing delays. FY2025 revenue reached £23m, with c.£4m of expected contracts shifting into FY2026, supporting a record forward order book of ~£14m—more than double the prior year—and an investment-grade pipeline exceeding £127m. Adjusted EBITDA rose 183% year-on-year to £1.7m, reflecting solid organic growth, disciplined cost control, and stable margins (35.3% gross margin overall; >40% in LED and ~30% in solar). The Group’s growth strategy—pivoting from direct sales to partner-led frameworks and diversified routes to market—is delivering results, underpinned by major government, NHS, local authority, and commercial awards. E Energy now operates a scalable, multi-technology EPC platform spanning energy efficiency, solar (rooftop, ground-mount, and carports), battery storage, EV, and O&M, with increasing recurring revenue streams. A differentiated off-balance-sheet funding solution via a £100m Redaptive facility (IFRS 16 compliant) is accelerating deal flow, while technology investments and AI-enabled tools have materially improved conversion rates and delivery efficiency. Net debt reduced to £1.6m, liquidity is expected to strengthen as working capital unwinds, and governance was enhanced with the appointment of a new non-executive director and auditor transition. Looking ahead, management upgraded FY2026 guidance to £34m revenue and £4.5m adjusted EBITDA, citing strong visibility, a growing order book, and momentum across core sectors including education, healthcare, commercial real estate, and sports and leisure.

Ilika (IKA:AIM) delivered a comprehensive investor update outlining strong operational progress across its two solid-state battery platforms, reinforcing its near-term commercialisation strategy and long-term growth potential. During the period, the company strengthened its balance sheet through a successful equity raise and advanced its Stereax miniature solid-state batteries toward revenue generation, having qualified manufacturing with US partner Cirtec Medical, commenced production, delivered initial batteries to customers, and received its first commercial purchase order for cathode materials—marking an important inflection point for recurring revenues, royalties, and licensing income. Stereax targets fast-growing medical and industrial IoT markets, with applications in neurostimulation, implantable sensors, orthopaedics, ophthalmics, and digital health, supported by a capital-light licensing model and a growing patent portfolio of 78 granted patents. Progress was also reported on Goliath, Ilika’s large-format solid-state battery technology for automotive, industrial, defence, and consumer applications, with successful validation of prototype cells, commissioning of an automated pilot line, shipments of 10Ah power prototypes to OEMs and Tier-1 partners, and demonstrated compatibility with gigafactory-scale equipment at the UK Battery Industrialisation Centre. Independent modelling highlighted potential EV battery pack cost reductions, weight savings, faster charging, and improved range, supporting commercial discussions and licensing opportunities. Financially, the company reported revenue of £0.6m, an increased EBITDA loss reflecting accelerated development activity, and a cash balance of £6.9m post-period, further supported by R&D tax credits and ongoing grant funding. Overall, Ilika enters the next phase with improving order momentum, multiple revenue streams, and a clear path to scalable commercial partnerships.

Shield Therapeutics PLC (STX:AIM) provided a detailed investor update covering Q4 and full-year 2025, highlighting strong company performance, accelerating US commercialization, and a pivotal shift to cash flow positivity. The specialty pharmaceutical group, focused on iron deficiency (ID) and iron deficiency anaemia (IDA), reported total 2025 revenues of nearly $50 million, including $46 million from its flagship product Accrufer®/Feraccru®, representing 56% year-on-year growth in the US. Nearly 200,000 prescriptions were dispensed during the year, up 33%, supported by a higher net selling price of approximately $223 and continued gains in market access, establishing Accrufer as the number one branded prescription oral iron in the US. The company turned cash flow positive in Q4 2025 for the first time, ending the year with $11.6 million in cash, improved debt terms, and expanded financial flexibility to support growth and potential M&A. Shield outlined a clear growth strategy focused on increasing awareness through direct-to-consumer marketing, expanding prescriber reach across primary care, women’s health and select specialists, improving reimbursement and prior authorisation processes, and driving further prescription growth. International expansion also progressed, with launches in Canada, regulatory approvals in South Korea and paediatric indications in the US, filings planned in China, and a Phase II trial underway in Japan. Looking ahead, Shield targets continued revenue growth, improved margins, EBIT profitability in 2026, and portfolio diversification through additional products alongside Accrufer.

The Works.Co.Uk plc (WRKS:AIM) reported a strong investor update highlighting significant strategic and financial progress in the first half of FY26, underpinned by resilient store performance, expanding margins, and disciplined cost control. Despite a challenging UK retail backdrop and material online fulfilment disruption, the group delivered store like-for-like sales growth of 4%, outperforming the wider non-food market, while total revenue reached £123.8m. Product margin increased by 330bps to 62.6%, driven by improved buying, tighter stock management, selective pricing actions, and favourable freight and FX dynamics, supporting a marked improvement in profitability. Pre-IFRS 16 EBITDA improved to a £1.0m loss in H1 versus a £2.8m loss last year, with net debt reduced to £5.3m. Online sales declined sharply due to capacity constraints following the transition to a new third-party fulfilment provider, but management confirmed trading remains in line with expectations and reiterated full-year FY26 EBITDA guidance of £11m, up from £9.5m in FY25. The group continues to execute its “Elevating The Works” growth strategy, focused on brand awareness, customer convenience, and operational efficiency, supported by a profitable store estate of over 500 locations, ongoing store openings, and targeted capital investment. Looking ahead, The Works expects further sales and profit growth in FY27, supported by continued margin progression, additional cost savings, store estate expansion, and resolution of online fulfilment challenges, reinforcing confidence in its medium-term growth strategy and EBITDA margin expansion.